Enforcement against illicit alternative nicotine products on the US market has come to the fore since the Food and Drug Administration (FDA)’s budget for the first time includes a minimum floor for it.
But there appears to be a disconnect in how leadership at the FDA and the wider Department of Health and Human Services (HHS) discuss vaping.
For the first time ever, a minimum – of $200m – has been specified to be spent on enforcement activities specifically against illicit vaping products in the US market for the 2026 fiscal year.
